{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T17:29:13Z","timestamp":1794158953306,"version":"4.8.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Given the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared the long\u2010term outcomes of NAFLD and MAFLD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We included patients with fatty liver disease (FLD) from NHANES III and NHANES 2017\u20132018 (FLD defined as moderate to severe hepatic steatosis by ultrasound for NHANES III and as having a controlled attenuation parameter \u2265285 dB\/m for NHANES 2017\u20132018). NAFLD was defined as FLD without other liver diseases and excess alcohol use. Metabolic\u2010associated fatty liver disease (MAFLD) was defined as FLD and metabolic dysfunction per criteria. All NHANES III participants had linked mortality data through December 31, 2015.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>NHANES III participants (<jats:italic toggle=\"yes\">n<\/jats:italic> = 12,878): mean age 43.1 years old; 49.5% male; 20.3% with FLD, 16.5% with NAFLD, and 18.1% with MAFLD. NHANES 2017\u20132018 participants (<jats:italic toggle=\"yes\">n<\/jats:italic> = 4328): mean age 48.0 years old; 49.1% male; 36.8% with FLD, 34.2% with NAFLD, and 36.3% with MAFLD. Excellent concordance was noted between MAFLD and NAFLD diagnosis in both data sets (kappa coefficient = 0.83\u20130.94). Except for components of each definition (e.g., alcohol use for MAFLD), no other major differences in clinical characteristics were noted. During up to 27 years of follow\u2010up (median of 22.8 years), no differences in cumulative all\u2010cause and cause\u2010specific mortality were noted. In addition to the stage of fibrosis, insulin resistance was a predictor of liver mortality in NAFLD, and alcohol\u2010associated liver disease (ALD) was a predictor of mortality in MAFLD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>MAFLD and NAFLD have similar clinical profiles and long\u2010term outcomes. The increased liver\u2010related mortality among NAFLD is driven by insulin resistance, and among MAFLD is primarily driven by ALD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.32499","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:18:58Z","timestamp":1648840738000},"page":"1423-1437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":170,"title":["Are there outcome differences between NAFLD and metabolic\u2010associated fatty liver disease?"],"prefix":"10.1097","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[{"name":"3313,Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,Virginia,USA"},{"name":"Center for Liver Disease,Department of Medicine,Inova Fairfax Medical Campus,Falls Church,Virginia,USA"},{"name":"3313,Inova Medicine,Inova Health System,Falls Church,Virginia,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Paik","sequence":"additional","affiliation":[{"name":"3313,Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,Virginia,USA"},{"name":"Center for Liver Disease,Department of Medicine,Inova Fairfax Medical Campus,Falls Church,Virginia,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Al Shabeeb","sequence":"additional","affiliation":[{"name":"3313,Inova Medicine,Inova Health System,Falls Church,Virginia,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Golabi","sequence":"additional","affiliation":[{"name":"3313,Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,Virginia,USA"},{"name":"Center for Liver Disease,Department of Medicine,Inova Fairfax Medical Campus,Falls Church,Virginia,USA"},{"name":"3313,Inova Medicine,Inova Health System,Falls Church,Virginia,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issah","family":"Younossi","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research in Liver Diseases,Washington,DC,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"3313,Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,Virginia,USA"},{"name":"3313,Inova Medicine,Inova Health System,Falls Church,Virginia,USA"},{"name":"Center for Outcomes Research in Liver Diseases,Washington,DC,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"issue":"7","key":"hep32499-bib-0001-20241017","first-page":"434","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"hep32499-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","year":"2020","journal-title":"Gut"},{"issue":"1","key":"hep32499-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32499-bib-0004-20241017","first-page":"S1","article-title":"Global prevalence of nonalcoholic steatohepatitis (NASH): findings from a targeted literature review","volume":"21","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"hep32499-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans","volume":"14","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"hep32499-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","year":"1999","journal-title":"Gastroenterology"},{"key":"hep32499-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","year":"2010","journal-title":"Gut"},{"key":"hep32499-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of followup biopsies reveals disease progression in patients with nonalcoholic fatty liver","volume":"59","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"hep32499-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta\u2010analysis of paired\u2010biopsy studies","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32499-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"hep32499-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"100305","DOI":"10.1016\/j.jhepr.2021.100305","article-title":"Epidemiology of non\u2010alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"hep32499-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"hep32499-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"hep32499-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with non\u2010alcoholic steatohepatitis (NASH) in the United States","volume":"69","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"hep32499-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non\u2010alcoholic steatohepatitis in East Asia: data from Hong Kong","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"issue":"10","key":"hep32499-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.14309\/ajg.0000000000000375","article-title":"Patients with nonalcoholic steatohepatitis experience severe impairment of health\u2010related quality of life","volume":"114","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"hep32499-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy\u2010proven nonalcoholic steatohepatitis","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"hep32499-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep4.1710","article-title":"Improvements of fibrosis and disease activity are associated with improvement of patient\u2010reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"5","year":"2021","journal-title":"Hepatol Commun"},{"key":"hep32499-bib-0019-20241017","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18\u2010month interim analysis","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"hep32499-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"hep32499-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden\u2014Saudi Arabia and United Arab Emirates, 2017\u20132030","volume":"24","year":"2018","journal-title":"Saudi J Gastroenterol"},{"issue":"11","key":"hep32499-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","year":"2021","journal-title":"Hepatol Commun"},{"key":"hep32499-bib-0023-20241017","article-title":"A global survey of physicians knowledge about nonalcoholic fatty liver disease","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"hep32499-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.13035","article-title":"Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011\u20132016","volume":"287","year":"2020","journal-title":"J Intern Med"},{"issue":"3","key":"hep32499-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"hep32499-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep32499-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep4.1387","article-title":"Mortality risk detected by atherosclerotic cardiovascular disease score in participants with nonalcoholic fatty liver disease","volume":"3","year":"2019","journal-title":"Hepatol Commun"},{"issue":"2","key":"hep32499-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in participants with nonalcoholic fatty liver disease","volume":"39","year":"2019","journal-title":"Liver Int"},{"issue":"7","key":"hep32499-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"hep32499-bib-0030-20241017","article-title":"Trends in the burden of chronic liver disease among hospitalized US adults","volume":"3","year":"2020","journal-title":"JAMA Network Open"},{"issue":"7","key":"hep32499-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus\u2010driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"hep32499-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction\u2010associated fatty liver disease: an international expert consensus statement","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32499-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies","volume":"9","year":"2011","journal-title":"BMC Med"},{"issue":"6","key":"hep32499-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction\u2010associated fatty liver disease is associated with increased all\u2010cause mortality in the United States","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"12","key":"hep32499-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"hep32499-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"hep32499-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jhep.2020.08.028","article-title":"The times they are a\u2010changin\u2019 (for NAFLD as well)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"issue":"32","key":"hep32499-bib-0038-20241017","first-page":"1","article-title":"Plan and operation of the Third National Health and Nutrition Examination Survey, 1988\u201394","year":"1994","journal-title":"Vial Health Stat 1"},{"issue":"5","key":"hep32499-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32499-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2214\/AJR.15.14552","article-title":"Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques","volume":"205","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"hep32499-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"hep32499-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1148\/radiol.2015150619","article-title":"Elastography assessment of liver fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement","volume":"276","year":"2015","journal-title":"Radiology"},{"key":"hep32499-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration\u2010controlled transient elastography to assess fibrosis and steatosis in participants with nonalcoholic fatty liver disease","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32499-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.cgh.2020.08.017","article-title":"Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017\u20132018","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32499-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","year":"2012","journal-title":"Medicine"},{"key":"hep32499-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apt.15580","article-title":"The impact of modifiable risk factors on the long\u2010term outcomes of non\u2010alcoholic fatty liver disease","volume":"51","year":"2020","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32499","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:51:20Z","timestamp":1729209080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32499","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2022-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}